Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Company

Integragen


Genopole Campus 1 – 5, rue Henri Desbruères
91030 EVRY Cedex – FRANCE
Phone: +33 1 60 91 09 00
Email: contact@integragen.com

Bernard COURTIEU: CEO
Web Site >
Logo Integragen - Genopole's Company Logo Integragen - Genopole's Company

#Health / Well-being #Diagnostics

  • Autism
  • Oncology
  • Metabolism
  • Diagnostics
  • Genetics

Field of Activity


IntegraGen’s mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests based on these discoveries. The company also strives to be a leader in cutting edge genomic services to academic researchers and life sciences companies based on its technological expertise and scientific know how.

BACKGROUND
IntegraGen was founded in 2000 on the basis of a locus identification technology for familial, polygenic diseases. The company rapidly built a portfolio of patents protecting its discoveries in the field of genetic predispositions.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
Unique personalized sequencing services.

  • Expert pharmacogenomics services (sequencing and genotyping) to research organizations on a CRO basis.
  • Diagnostics: IntegraGen is developing panels of biomarkers likely to indicate an increased risk of disease onset (in autism and oncology), contributing to early molecular diagnosis and treatment.

CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS

  • Dec 2015: IntegraGen announced a collaboration with investigators from the FIRE-3 clinical trial to further study the oncology biomarker miR-31-3p, a microRNA whose expression has been shown to be associated with anti-EGFR e ect in patients with metastatic colorectal cancer.
  • July 2015: IntegraGen and the Georges Pompidou European Hospital (HEGP) announced the signing of an agreement to develop the use of high-throughput sequencing techniques to improve the care of patients.
  • June 2015: Results from two new studies exploring the role of the biomarker miR-31-3p in patients with metastatic colorectal cancer were presented during the 2015 ASCO Annual Meeting. The studies reported positive results on the association between miR-31-3p expression and clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with panitumumab or cetuximab.
  • March 2015: The Institut Pasteur and IntegraGen announced the signing of a partnership agreement making IntegraGen the operator of sequencing activities for the National Reference Centers (NRC) and microbiological collections of the Institut Pasteur.

COLLABORATIONS SOUGHT
In order to develop innovative and clinically useful diagnostic tools, IntegraGen controls the entire Genomic Diagnostics Services development chain:

  • Technological leadership and command of state-of- the- art genomics, particularly command of technologies such as high bit-rate sequencing and genotyping and, in more general terms, all technologies relative to analysis of DNA and genetic cell material.
  • Integration of academic or private research into the networks as partner or service providers.
  • Establishment of networks of clinical practitioners specialized in targeted pathologies where the tools developed serve to improve patient care.
  • Control of the biostatistics and bioinformatics validation aspects.
  • Perfect knowledge of regulatory aspects.
  • Access to reference laboratory markets in Europe and North America. IntegraGen’s vocation is to be number 1 in the genetic test field, thus contributing to diagnostics and improving care for targeted pathologies such as autism and certain forms of cancer.
  • Further Information

    CA 2019 : 8.3 M€
    11 Patents
    46 Staff members

    Strenghts

    Growing turnover
    Validated diagnostic tools.
    Academic partners

    LES FORCES

    Outils diagnostiques moléculaires validés.
    Partenariats académiques.
    Innovation assets
    State-of-the-art equipment (HiSeq / MiSeq IlluminaTM), unique in France. Personalized sequencing services. Contract offers

Share
Genopole’s Companies

#Diagnostics


in same field

Cell Environment - Genopole's company

Cell Environment

Cell Environment is a company focusing on DNA damage detection involving unique and repeated sequences such as telomere and centromere sequences.

Discover
Innovhem - Entreprise génopolitaine

Innovhem

Our mission is to improve the management of Red Blood Cell diseases and in particular Sickle Cell Disease

Discover
logo GenoSplice - Genopole's Company

GenoSplice

Bioinformatics service provider (gene expression, splicing, SNP, CNV, epigenetics, data integration).

Discover
Endodiag - Genopole's company

Endodiag

Design, development and commercialization of medical devices and services for the diagnosis of endometriosis.

Discover
Enalees - Genopole's company

Enalees

Enalees conceives, develops and markets next-generation rapid molecular diagnosis tests for veterinarians, and furthermore screening tests for SARS-CoV-2.

Discover
AgenT Biotech - entreprise génopolitaine

AgenT

AgenT is developing an unprecedented blood test to identify patients with Alzheimer's disease much earlier in disease course than current detection methods are able to do. The company also does drug repositioning research to identify compounds potentially active in the silent phase of Alzheimer's disease.

Discover
View all >
With the support from